Neuromuscular

Episodes 17-32 of 32

• 

  RestartResume

  The Science Behind FcRn Antagonists: A Deep Dive Into Their Mechanism of Action

  RestartResume

  The Science Behind FcRn Antagonists: A Deep Dive Into Their Mechanism of Action

  MinuteCE®

  The Science Behind FcRn Antagonists: A Deep Dive Into Their Mechanism of Action

  Nicholas J. Silvestri, MD; James F. Howard, Jr, MD

  1.00 program credit

  Nicholas J. Silvestri, MD; James F. Howard, Jr, MD

  1.00 program credit

• 

  RestartResume

  FcRn Antagonists in Myasthenia Gravis: A New Era in Targeted Therapy 

  RestartResume

  FcRn Antagonists in Myasthenia Gravis: A New Era in Targeted Therapy 

  MinuteCE®

  FcRn Antagonists in Myasthenia Gravis: A New Era in Targeted Therapy 

  Nicholas J. Silvestri, MD; James F. Howard, Jr, MD

  1.00 program credit

  Nicholas J. Silvestri, MD; James F. Howard, Jr, MD

  1.00 program credit

• 

  RestartResume

  Optimizing FcRn Therapy: Addressing and Reducing Adverse Reactions 

  RestartResume

  Optimizing FcRn Therapy: Addressing and Reducing Adverse Reactions 

  MinuteCE®

  Optimizing FcRn Therapy: Addressing and Reducing Adverse Reactions 

  Nicholas J. Silvestri, MD; James F. Howard, Jr, MD

  1.00 program credit

  Nicholas J. Silvestri, MD; James F. Howard, Jr, MD

  1.00 program credit

• 

  RestartResume

  Precision Medicine in Myasthenia Gravis: Crafting Personalized Treatment Strategies 

  RestartResume

  Precision Medicine in Myasthenia Gravis: Crafting Personalized Treatment Strategies 

  MinuteCE®

  Precision Medicine in Myasthenia Gravis: Crafting Personalized Treatment Strategies 

  Nicholas J. Silvestri, MD; James F. Howard, Jr, MD

  1.00 program credit

  Nicholas J. Silvestri, MD; James F. Howard, Jr, MD

  1.00 program credit

• 

  RestartResume

   Pinpointing CIDP: Diagnosis Challenges and Misdiagnosis/Delayed Diagnosis of CIDP

  RestartResume

   Pinpointing CIDP: Diagnosis Challenges and Misdiagnosis/Delayed Diagnosis of CIDP

  MinuteCE®

   Pinpointing CIDP: Diagnosis Challenges and Misdiagnosis/Delayed Diagnosis of CIDP

  Jeffrey Allen, MD; Nicholas J. Silvestri, MD

  1.00 program credit

  Jeffrey Allen, MD; Nicholas J. Silvestri, MD

  1.00 program credit

• 

  RestartResume

  Decoding CIDP: Exploring Common and Atypical Variants

  RestartResume

  Decoding CIDP: Exploring Common and Atypical Variants

  MinuteCE®

  Decoding CIDP: Exploring Common and Atypical Variants

  Jeffrey Allen, MD; Nicholas J. Silvestri, MD

  1.00 program credit

  Jeffrey Allen, MD; Nicholas J. Silvestri, MD

  1.00 program credit

• 

  MinuteCE®

  Incorporating FcRn Inhibitors Into Clinical Practice in Chronic Inflammatory Demyelinating Polyneuropathy

  Jeffrey Allen, MD; Nicholas J. Silvestri, MD

  1.00 credit 10 episodes

  Jeffrey Allen, MD; Nicholas J. Silvestri, MD

  1.00 credit 10 episodes

• 

  RestartResume

  Clinical Benefits of FcRn Inhibitors: Innovations in CIDP Management and Treatment

  RestartResume

  Clinical Benefits of FcRn Inhibitors: Innovations in CIDP Management and Treatment

  MinuteCE®

  Clinical Benefits of FcRn Inhibitors: Innovations in CIDP Management and Treatment

  Nicholas J. Silvestri, MD; Jeffrey Allen, MD

  1.00 program credit

  Nicholas J. Silvestri, MD; Jeffrey Allen, MD

  1.00 program credit

• 

  RestartResume

  Comprehensive CIDP Care: The Role of Multidisciplinary Teams and Patient-Reported Outcomes

  RestartResume

  Comprehensive CIDP Care: The Role of Multidisciplinary Teams and Patient-Reported Outcomes

  MinuteCE®

  Comprehensive CIDP Care: The Role of Multidisciplinary Teams and Patient-Reported Outcomes

  Jeffrey Allen, MD; Nicholas J. Silvestri, MD

  1.00 program credit

  Jeffrey Allen, MD; Nicholas J. Silvestri, MD

  1.00 program credit

• 

  RestartResume

  Novel Mechanisms of Action: FcRn Inhibitors

  RestartResume

  Novel Mechanisms of Action: FcRn Inhibitors

  MinuteCE®

  Novel Mechanisms of Action: FcRn Inhibitors

  Jeffrey Allen, MD; Nicholas J. Silvestri, MD

  1.00 program credit

  Jeffrey Allen, MD; Nicholas J. Silvestri, MD

  1.00 program credit

• 

  RestartResume

  Implementing CIDP Clinical Guidelines: Optimizing Therapy

  RestartResume

  Implementing CIDP Clinical Guidelines: Optimizing Therapy

  MinuteCE®

  Implementing CIDP Clinical Guidelines: Optimizing Therapy

  Nicholas J. Silvestri, MD; Jeffrey Allen, MD

  1.00 program credit

  Nicholas J. Silvestri, MD; Jeffrey Allen, MD

  1.00 program credit

• 

  RestartResume

  CIDP Monitoring Challenges: Suboptimal Responses in CIDP Treatment

  RestartResume

  CIDP Monitoring Challenges: Suboptimal Responses in CIDP Treatment

  MinuteCE®

  CIDP Monitoring Challenges: Suboptimal Responses in CIDP Treatment

  Jeffrey Allen, MD; Nicholas J. Silvestri, MD

  1.00 program credit

  Jeffrey Allen, MD; Nicholas J. Silvestri, MD

  1.00 program credit

• 

  RestartResume

  Why Early and Accurate CIDP Diagnosis Matters: The Role of Standardized Tools

  RestartResume

  Why Early and Accurate CIDP Diagnosis Matters: The Role of Standardized Tools

  MinuteCE®

  Why Early and Accurate CIDP Diagnosis Matters: The Role of Standardized Tools

  Jeffrey Allen, MD; Nicholas J. Silvestri, MD

  1.00 program credit

  Jeffrey Allen, MD; Nicholas J. Silvestri, MD

  1.00 program credit

• 

  RestartResume

  Navigating CIDP Treatments: IVIg and Steroid Advantages and Limitations

  RestartResume

  Navigating CIDP Treatments: IVIg and Steroid Advantages and Limitations

  MinuteCE®

  Navigating CIDP Treatments: IVIg and Steroid Advantages and Limitations

  Jeffrey Allen, MD; Nicholas J. Silvestri, MD

  1.00 program credit

  Jeffrey Allen, MD; Nicholas J. Silvestri, MD

  1.00 program credit

• 

  RestartResume

  Autoantibodies in CIDP: Prevalence and Diagnostic Implications

  RestartResume

  Autoantibodies in CIDP: Prevalence and Diagnostic Implications

  MinuteCE®

  Autoantibodies in CIDP: Prevalence and Diagnostic Implications

  Jeffrey Allen, MD; Nicholas J. Silvestri, MD

  1.00 program credit

  Jeffrey Allen, MD; Nicholas J. Silvestri, MD

  1.00 program credit

• 

  RestartResume

  Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)

  RestartResume

  Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)

  CME/CE

  Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)

  John Russell, MD; Noel Dasgupta, MD, FACC

  0.50 credits

  John Russell, MD; Noel Dasgupta, MD, FACC

  0.50 credits